dc.contributor.author |
Luk, Franka |
dc.contributor.author |
Carreras-Planella, Laura |
dc.contributor.author |
Korevaar, Sander S. |
dc.contributor.author |
de Witte, Samantha F. H. |
dc.contributor.author |
Borràs i Serres, Francesc Enric |
dc.contributor.author |
Betjes, Michiel G. H. |
dc.contributor.author |
Baan, Carla C. |
dc.contributor.author |
Hoogduijn, Martin J. |
dc.contributor.author |
Franquesa, Marcella |
dc.date |
2017 |
dc.identifier |
https://ddd.uab.cat/record/196875 |
dc.identifier |
urn:10.3389/fimmu.2017.01042 |
dc.identifier |
urn:oai:ddd.uab.cat:196875 |
dc.identifier |
urn:pmid:28894451 |
dc.identifier |
urn:scopus_id:85028442641 |
dc.identifier |
urn:wos_id:000408404800002 |
dc.identifier |
urn:altmetric_id:26970516 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/9975608c-4f2c-4776-817d-14a6aa682932 |
dc.identifier |
urn:pmc-uid:5581385 |
dc.identifier |
urn:pmcid:PMC5581385 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5581385 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014BP B00118 |
dc.relation |
Frontiers in immunology ; Vol. 8 (august 2017), p. 1-13 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
B cell |
dc.subject |
Immunomodulation |
dc.subject |
Mesenchymal stem cell |
dc.subject |
Plasmablast |
dc.subject |
Regulatory B cell |
dc.subject |
Indoleamine |
dc.subject |
2,3-dioxygenase |
dc.title |
Inflammatory conditions dictate the effect of Mesenchymal stem or Stromal cells on B cell function |
dc.type |
Article |
dc.description.abstract |
The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a promising tool for treatment of immune disease and organ transplantation. The effects of MSC on B cells are characterized by an abrogation of plasmablast formation and induction of regulatory B cells (Bregs). It is, however, unknown how MSC interact with B cells under inflammatory conditions. In this study, adipose tissue-derived MSC were pretreated with 50 ng/ml IFN-γ for 96 h (MSC-IFN-γ) to simulate inflammatory conditions. Mature B cells were obtained from spleens by CD43− selection. B cells were co-cultured with MSC and stimulated with anti-IgM, anti-CD40, and IL-2; and after 7 days, B cell proliferation, phenotype, Immunoglobulin-G (IgG), and IL-10 production were analyzed. MSC did not inhibit B cell proliferation but increased the percentage of CD38high CD24high B cells (Bregs) and IL-10 production, while MSC-IFN-γ significantly reduced B cell proliferation and inhibited IgG production by B cells in a more potent fashion but did not induce Bregs or IL-10 production. Both MSC and MSC-IFN-γ required proximity to target cells and being metabolically active to exert their effects. Indoleamine 2,3 dioxygenase expression was highly induced in MSC-IFN-γ and was responsible of the anti-proliferative and Breg reduction since addition of tryptophan (TRP) restored MSC properties. Immunological conditions dictate the effect of MSC on B cell function. Under immunological quiescent conditions, MSC stimulate Breg induction; whereas, under inflammatory conditions, MSC inhibit B cell proliferation and maturation through depletion of TRP. This knowledge is useful for customizing MSC therapy for specific purposes by appropriate pretreatment of MSC. |